<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104739</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-13-0791</org_study_id>
    <nct_id>NCT02104739</nct_id>
  </id_info>
  <brief_title>Effects of Antidiabetic Medications on the Postprandial State in Prediabetes</brief_title>
  <official_title>Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project addresses cardiovascular disease risk in patients with prediabetes.  Levels of
      lipids after eating a meal (&quot;postprandial lipids&quot;) are strong independent predictors of
      cardiovascular risk. Newer anti-diabetic agents - exenatide, saxagliptin, and pioglitazone -
      impact lipid metabolism.  These medications will be studied for their effect in reducing
      both postprandial lipid levels and arterial dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a paradox that medical efforts to control blood glucose in type 2 diabetes mellitus
      have not decreased the risk of cardiovascular disease. Postprandial lipid concentrations are
      a strong predictor of cardiovascular risk, independent of traditional cardiovascular risk
      factors. The new classes of antidiabetic medications - GLP-1 agonists, DPP-IV inhibitors,
      and PPAR-λ agonists - affect lipid as well as glucose metabolism. This study will
      investigate the efficacy of these medications in reducing postprandial hyperlipidemia,
      disrupting the concurrent proinflammatory free fatty acid signaling, and ameliorating
      endothelial dysfunction in individuals with prediabetes. This will consist of a single
      center, randomized, crossover, placebo-controlled double-blinded prospective trial involving
      four study arms representing the aforementioned medications: exenatide (GLP-1 agonist),
      saxagliptin (DPP-IV inhibitor), pioglitazone (PPAR-λ agonist), and placebo (control arm).
      For each study arm, subjects will eat a standardized atherogenic high-fat test lunch. Venous
      blood draws and measurements of forearm blood flow will be done prior to the meal and
      periodically during a 6-hour period after the meal. Forearm blood flow measurements will
      assess for changes in endothelial function. The blood will be analyzed for multiple markers
      of hyperlipidemia and free fatty acid signaling. The results will provide new insights into
      the anti-inflammatory effects of multiple antidiabetic medications via the mechanisms of
      postprandial hyperlipidemia, free fatty acid signaling, and endothelial function in
      prediabetic individuals
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Free Fatty Acids</measure>
    <time_frame>6 hours after ingestion of meal</time_frame>
    <safety_issue>No</safety_issue>
    <description>Free Fatty Acids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>6 hours after ingestion of meal</time_frame>
    <safety_issue>No</safety_issue>
    <description>triglycerides</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Forearm blood flow</measure>
    <time_frame>6 hours after meal</time_frame>
    <safety_issue>No</safety_issue>
    <description>Forearm blood flow via strain gauge venous occlusion plethysmography</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prediabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin 5 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pioglitazone 45 mg orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide 10 mcg subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Single subcutaneous injection (10 mcg)</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Single dose orally (5 mg)</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Single dose orally (45 mg)</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets and Placebo (normal saline) injections</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, ages 30 to 70 years of age inclusive

          2. Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting
             glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood
             glucose of 140-199 mg/dL after 75 gram oral glucose challenge), and/or a hemoglobin
             A1C ranging from 5.7% to 6.4%

          3. Subjects are allowed, but not required, to be on statins, ACE-inhibitors, and
             angiotensin-receptor blockers at doses that have been stable for at least the last 3
             months

          4. BMI between 30-35 kg/m2

          5. Body weight has been stable (±4-5 pounds) over the prior three months.

          6. Women of childbearing age must agree to use an acceptable method of pregnancy
             prevention (barrier methods, abstinence, or surgical sterilization) for the duration
             of the study

          7. Patients must have the following laboratory values: Hematocrit ≥ 34 vol%, serum
             creatinine &lt; 1.5 mg/dl in men and  &lt;1.4 mg/dl in women, aspartate aminotransferase  &lt;
             2.5 times upper limit of normal, alanine aminotransferase &lt; 2.5 times upper limit of
             normal, alkaline phosphatase&lt; 2.5 times upper limit of normal

        Exclusion Criteria:

          1. History of Type 1 or Type 2 diabetes mellitus

          2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma

          3. Pregnant or breastfeeding women

          4. Patients must not be receiving lipid-lowering medications other than statins within
             the last 3 months

          5. Patient must not be receiving metformin, DPP-IV inhibitors, GLP-1 agonists,
             thiazolidinediones, insulin, sulfonylureas, acarbose, sodium-glucose cotransporter-2
             inhibitors, nonsteroidal antiinflammatory drugs, corticosteroids, immunosuppressive
             therapy, and antioxidant vitamins within the last 3 months

          6. Patients must not be receiving any of the following medications: thiazide or
             furosemide diuretics, beta-blockers, or other chronic medications such as hormone
             replacement therapy with known adverse effects on glucose tolerance levels.

          7. Patients with diabetic gastroparesis

          8. Patients with current tobacco use

          9. Patients with active malignancy

         10. Patients with history of urinary bladder cancer

         11. Patients with dietary restrictions precluding a high-fat meal

         12. Patients with a history of clinically significant heart disease (NYHA III or IV; more
             than non-specific ST-T wave changes on the EKG), peripheral vascular disease (history
             of claudication), or pulmonary disease (dyspnea on exertion of one flight or less;
             abnormal breath sounds on auscultation) will not be studied

         13. Subjects with a history of any serious hypersensitivity reaction to the study
             medications

         14. Prisoners, or subjects who are involuntarily incarcerated

         15. Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness

         16. Subjects with known allergic reactions to the study medications or test meal

         17. Subjects unwilling or unable to provide informed consent

         18. Subjects determined by the investigator(s) to not be appropriate candidates for the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Absalaon D Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center at Houston, Dept. of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Absalon D Gutierrez, MD</last_name>
    <phone>713-500-6641</phone>
    <email>absalon.d.gutierrez@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monika A Ruscheinsky, MS</last_name>
    <phone>713-704-0825</phone>
    <email>monika.ruscheinsky@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Absalon D Gutierrez, MD</last_name>
      <phone>713-500-6641</phone>
      <email>absalon.d.gutierrez@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monika A Ruscheinsky, MS</last_name>
      <phone>713-704-4137</phone>
      <email>monika.ruscheinsky@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Absalon D Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinrich Taegtmeyer, MD, DPhil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Orlander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Absalon D Gutierrez</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>exenatide</keyword>
  <keyword>saxagliptin</keyword>
  <keyword>pioglitazone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
